Learn About Proteus-Like Syndrome

What is the definition of Proteus-Like Syndrome?
Proteus-like syndrome describes people who do not meet the diagnostic criteria for Proteus syndrome but who share many of the characteristic signs and symptoms associated with the condition. Affected people may experience some of the following features: overgrowth of the bones, skin, and other tissues; hamartomas; abnormalities of the skin, blood vessels (vascular tissue) and fat (adipose tissue); and distinctive facial features. Approximately 50% of people with Proteus-like syndrome are found to have changes in the PTEN gene. In these cases, the inheritance is autosomal dominant.
Save information for later
Sign Up
Who are the top Proteus-Like Syndrome Local Doctors?
RH
Rudolf Happle
Distinguished
Highly rated in
65
conditions

University Of Freiburg

Freiburg, BW, DE 

Rudolf Happle is in Freiburg, Germany. Happle is rated as a Distinguished expert by MediFind in the treatment of Proteus-Like Syndrome. He is also highly rated in 65 other conditions, according to our data. His top areas of expertise are Cutis Marmorata Telangiectatica Congenita, Epidermal Nevus, Focal Dermal Hypoplasia, and Mosaicism.

View Profile
HS
Harvey B. Sarnat
Distinguished
Highly rated in
16
conditions

University Of Calgary And Alberta Children's Hospital Research Institute

Calgary, AB, CA 

Harvey Sarnat is in Calgary, Canada. Sarnat is rated as a Distinguished expert by MediFind in the treatment of Proteus-Like Syndrome. He is also highly rated in 16 other conditions, according to our data. His top areas of expertise are Hemimegalencephaly, Schizencephaly, Proteus-Like Syndrome, and Proteus Syndrome.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
MR
Martino Ruggieri
Distinguished
Highly rated in
56
conditions

University Of Catania

Postgraduate Training Program In Pediatrics, Department Of Clinical And Experimental Medicine 
Catania, IT 

Martino Ruggieri is in Catania, Italy. Ruggieri is rated as a Distinguished expert by MediFind in the treatment of Proteus-Like Syndrome. They are also highly rated in 56 other conditions, according to our data. Their top areas of expertise are Phacomatosis Pigmentovascularis, Neurofibromatosis, Blue Rubber Bleb Nevus Syndrome, and Clouston Syndrome.

View Profile
View All Doctors
What are the latest Proteus-Like Syndrome Clinical Trials?
Phase 1 Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
Who is this study for: Patients with Proteus syndrome
Status: Active, not recruiting
Start Date: November 16, 2015
Intervention Type: Drug
Phase: Phase 1
View Trial
Summary: Background:~Proteus syndrome (PS) is caused by a mutation in the AKT1 gene. This gene makes a protein that communicates with other proteins in the body to make cells grow. The AKT1 mutation changes chemical signals in the body and causes overgrowth. PS can be fatal. The drug MK-7075 reduces signals from the AKT1 protein. This may reduce or stabilize some of the overgrowth in people with PS. Resear...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multi-Cohort Phase 2 Dose-Escalation Study of MK-7075 (Miransertib) in Proteus Syndrome
Status: Recruiting
Start Date: May 20, 2022
Intervention Type: Drug
Phase: Phase 2
View Trial
Summary: Background:~Proteus syndrome is a rare overgrowth disorder. Most people begin to have symptoms between 6 months and 2 years of age. There are very few living adults with this disease. There is also no known treatment for it. Researchers want to see if a new drug can slow down or stop overgrowth in people with Proteus syndrome.~Objective:~The learn if miransertib is a safe and effective treatment f...
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Proteus-Like Syndrome?
Cardiothoracic imaging findings of Proteus syndrome.
Journal: Scientific reports
Published: March 23, 2021
View publication
Summary: Cardiothoracic imaging findings of Proteus syndrome.
Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment.
Condition: Prostatitis
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Treatment Used: Flomoxef
Number of Patients: 54
Published: December 12, 2019
View publication
Summary: Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment.
Tired of the same old research?
Check Latest Advances
Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
Condition: Proteus Syndrome
Journal: American journal of human genetics
Treatment Used: Miransertib
Number of Patients: 6
Published: February 27, 2019
View publication
Summary: Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
View All Latest Advances